Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma</p>
Thomas Ollila, İlyas Şahin, Adam J. Olszewski
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 1085-1094
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Rena Liu, Robert J. Oldham, Emma Teal, et al.
Antibodies (2020) Vol. 9, Iss. 4, pp. 64-64
Open Access | Times Cited: 167
Avidity in antibody effector functions and biotherapeutic drug design
Simone C. Oostindie, Greg A. Lazar, Janine Schuurman, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 10, pp. 715-735
Open Access | Times Cited: 143
Immunotherapy of Cancer by Targeting Regulatory T cells
Bo-Jin Chen, Jingwen Zhao, Dahong Zhang, et al.
International Immunopharmacology (2022) Vol. 104, pp. 108469-108469
Open Access | Times Cited: 76
Clinical significance of chemokine receptor antagonists
Miao Miao, Erik De Clercq, Guangdi Li
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 1, pp. 11-30
Closed Access | Times Cited: 111
Clinicopathological definition, management and prognostic value of mogamulizumab‐associated rash and other cutaneous events: A systematic review
Gianluca Avallone, Gabriele Roccuzzo, Alessandro Pileri, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 9, pp. 1738-1748
Open Access | Times Cited: 12
Bilayer lipids modulate ligand binding to atypical chemokine receptor 3
S.A. Eberle, Martin Gustavsson
Structure (2024) Vol. 32, Iss. 8, pp. 1174-1183.e5
Open Access | Times Cited: 9
MAIT cell homing in intestinal homeostasis and inflammation
Zhengyu Wu, Xingchi Chen, Fei Han, et al.
Science Advances (2025) Vol. 11, Iss. 6
Open Access | Times Cited: 1
CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driver
Jan P. Nicolay, Jana D. Albrecht, Silvia Alberti Violetti, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 7, pp. 1660-1671
Open Access | Times Cited: 42
Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma
Joselle Cook, Kah Whye Peng, Thomas E. Witzig, et al.
Blood Advances (2022)
Open Access | Times Cited: 32
Advances and Perspectives in the Treatment of T-PLL
Till Braun, Jana von Jan, Linus Wahnschaffe, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 113-124
Open Access | Times Cited: 44
Biased agonism at chemokine receptors
Dylan Scott Eiger, Noelia Boldizsar, Christopher Cole Honeycutt, et al.
Cellular Signalling (2020) Vol. 78, pp. 109862-109862
Open Access | Times Cited: 42
Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy
Gregory P. Takacs, Joseph Flores‐Toro, Jeffrey K. Harrison
Pharmacology & Therapeutics (2020) Vol. 222, pp. 107790-107790
Open Access | Times Cited: 40
What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?
Julien Catherine, Florence Roufosse
Seminars in Immunopathology (2021) Vol. 43, Iss. 3, pp. 439-458
Open Access | Times Cited: 39
Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function
Milad Rouhimoghadam, Anh S. Lu, Aliasger K. Salem, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 39
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma
Julia Scarisbrick, M. Bagot, Pablo L. Ortiz‐Romero
British Journal of Haematology (2020) Vol. 192, Iss. 4, pp. 683-696
Open Access | Times Cited: 33
Latest update on chemokine receptors as therapeutic targets
Wing Yee Lai, Anja Müeller
Biochemical Society Transactions (2021) Vol. 49, Iss. 3, pp. 1385-1395
Open Access | Times Cited: 32
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series
Nicholas A. Trum, Jasmine Zain, X. Martínez, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 1, pp. 153-166
Open Access | Times Cited: 32
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
Amy Musiek, Kerri E. Rieger, M. Bagot, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 29-40
Open Access | Times Cited: 31
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
Massimo Claudio Fantini, Philip M. Arlen, Kwong Y. Tsang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Chemokine receptors in COVID-19 infection
Claudia Gutierrez-Chavez, Shalom Aperrigue-Lira, Brando Ortiz-Saavedra, et al.
International review of cell and molecular biology (2024), pp. 53-94
Closed Access | Times Cited: 4
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas
Donald C. Moore, Joseph B. Elmes, Priscila A. Shibu, et al.
Annals of Pharmacotherapy (2019) Vol. 54, Iss. 4, pp. 371-379
Closed Access | Times Cited: 34
Chemokines and the extracellular matrix: Set of targets for tumor development and treatment
Paulo Silva, Bruna Cristina Borges, Isadora Akemi Uehara, et al.
Cytokine (2021) Vol. 144, pp. 155548-155548
Closed Access | Times Cited: 26
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial
Richard Cowan, Julia Scarisbrick, Pier Luigi Zinzani, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 11, pp. 2225-2238
Open Access | Times Cited: 26
NK Cell-Fc Receptors Advance Tumor Immunotherapy
Emilio Sanseviero
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1667-1667
Open Access | Times Cited: 27
CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
Zhaohui Wang, Jihong Ma, Huiping Zhang, et al.
FEBS Open Bio (2023) Vol. 13, Iss. 7, pp. 1309-1319
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top